Norfloxacin vs best parenteral therapy in treatment of moderate to serious, multiply-resistant, nosocomial urinary tract infections: a pharmacoeconomic analysis.
D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000892:Anti-Infective Agents, Urinary / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003365:Costs and Cost Analysis; D003428:Cross Infection / Q000188:drug therapy* / Q000191:economics; D004359:Drug Therapy, Combination; D006801:Humans; D009643:Norfloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D011897:Random Allocation; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000191:economics
D000900:Anti-Bacterial Agents; D000892:Anti-Infective Agents, Urinary; D009643:Norfloxacin